))
Lymphoma highlights at EHA 2023: sequencing bispecifics & CAR-T cells, bridging therapy & toxicity management
Manage episode 366255739 series 2838329
Indhold leveret af VJHemOnc. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af VJHemOnc eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
The treatment landscape of large B-cell lymphoma (LBCL) has transformed in recent years, with novel immunotherapies including bispecific antibodies and CAR-T cells demonstrating promising results. At the 2023 EHA meeting, leading experts from around the globe came together to discuss the latest updates in all areas of hematological oncology.
In this podcast, you will hear from Gloria Iacoboni, MD, Vall d’Hebron University Hospital, Barcelona, Spain, and Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, who share some insights into recent advances in CAR-T therapy and bispecific antibodies in the treatment of LBCL. Topics covered include the sequencing of these agents, bridging therapies, and managing toxicities and cytopenias after CAR-T therapy.
200 episoder
Del
